About this event

Advanced Therapies Europe 2026 — Deep Research Description & Buyer Targeting Analysis

Event Snapshot (Confirmed from Official Event Source)

• Event title: Advanced Therapies Europe 2026
• Dates: 7–9 September 2026
• Venue: InterContinental Barcelona
• City/Country: Barcelona, Spain
• Format (as described): Focused conference and networking event for the advanced therapies and regenerative medicine community
• Positioning: Intentionally intimate gathering for senior decision-makers, designed to drive high-impact conversations

Why This Event Matters for Advanced Therapies & Regenerative Medicine Buyers

Advanced Therapies Europe 2026 is a curated, senior-level platform centered on advanced therapies and regenerative medicine—specifically focused on innovation, investment, and bringing new treatments to market. The event is designed for decision-makers across European biotech and life sciences, and it emphasizes networking and discussions that translate into action (invest, scale, partner, launch).

For attendee-list intelligence and buyer targeting, this event typically converts best when we define buyers as decision stakeholders in: (1) therapy developers, (2) platform and technology providers supporting cell and gene therapy, (3) CDMOs and advanced manufacturing, (4) translational research and clinical operations leadership, and (5) investment and partnering roles who evaluate pipeline and execution readiness.

1️⃣ Who attends (BUYERS / ATTENDEES)

This event is explicitly described as an “advanced therapies and regenerative medicine community” conference and networking event, bringing together key people across European biotech and life sciences. It is designed for people working in cell and gene therapy, regenerative medicine, biotech investment, and manufacturing.

A) Core attendee groups (highest buyer probability)

• Senior executives at therapy developers (cell & gene therapy / regenerative medicine): CEOs, co-founders, and platform heads who set strategic partnering and funding priorities.
• Clinical and technical operations leadership: individuals responsible for clinical delivery, drug product operations, and scaling execution.
• Investment and partnership stakeholders: biotech investors, venture funds, strategic investment teams, and corporate/business development leaders evaluating investment and collaboration opportunities.
• Manufacturing and process development roles: leaders focused on manufacturing readiness, scale-up, quality, and technology transfer (often through CDMO partnerships or internal manufacturing expansions).
• Therapeutic developers & pharma stakeholders (ecosystem participation): organizations looking to partner, sponsor, or explore pipeline opportunities and technology integration.

B) “Buyer” definition for our attendee-list research

We recommend treating “buyers” as people who influence or own decisions around one of the following: investment, partnering, clinical/CMC execution strategy, manufacturing/vendor selection, or platform technology adoption. Because the event is intimate and senior-led, the attendee density for these decision roles is typically stronger than at large generic life sciences conferences.

2️⃣ Where the show is happening + attendee geographic origin

Venue and host location

• Venue: InterContinental Barcelona
• City: Barcelona
• Country: Spain
• Dates: 7–9 September 2026

Geographic origin of attendees

The event’s official highlights indicate 35+ countries represented (from the 2025 event highlights referenced on the official page). That suggests a Europe-led but internationally connected audience structure.

Practical buyer targeting implication: We should prioritize European biotech and investment decision-makers, while still capturing international pipeline partners that regularly engage with Europe’s advanced therapies ecosystem.

Best geographic targeting (recommended)

• Primary: Europe-wide (Spain, UK, Germany, France, Netherlands, Switzerland, Sweden, Denmark, Italy, Belgium, Ireland, etc.)
• Secondary: North America and select APAC organizations with European clinical/CMC and partnership footprints
• Strategic note: Barcelona is a strong life sciences hub within southern Europe, supporting higher attendance concentration from Iberia and cross-border European partnerships.

3️⃣ Audience reach (Local / National / Global)

This conference is best categorized as Global reach with a European center of gravity. While it is “curated for Europe,” the presence of 35+ countries represented indicates that the audience extends internationally through speakers, investing organizations, and multinational life sciences stakeholders.

• Local: Spain-focused visibility exists due to the host city and venue
• National: Strong for Spain-based biotech, academic, and investment communities
• Global: Confirmed by 35+ countries represented and typical cross-border advanced therapies partnering behavior

4️⃣ Sample buyer company names (BUYERS ONLY) + Websites

Below is a buyer-oriented sample list of advanced therapies ecosystem organizations that commonly align with the decision roles and priorities described for this event (innovation, investment, and bringing treatments to market). We should treat these as high-likelihood target accounts for buyer research workflows.

Important: this document is a research targeting framework. For final accuracy, we still recommend validating specific exhibitor/sponsor presence and confirmed attendee participation once we have the client’s profile requirements.

Sample Buyer Target Table (15–20 records)

“Best first 5” buyers to send early (high relevance to senior agenda)

1. Integra Therapeutics
2. uniQure
3. Orchard Therapeutics
4. Lonza
5. LifeLink Ventures

5️⃣ Job profiles, industries & event type

Event type (as described)

Advanced Therapies Europe 2026 is a focused conference and networking event for advanced therapies and regenerative medicine. It is curated for European senior decision-makers and is explicitly designed to discuss: innovation, investment, and bringing new treatments to market.

Job profiles to target (best buyer roles)

• Chief Executive Officer / Co-Founder (strategy, partnerships, fund-raising, scaling)
• Head of Advanced Therapies / Platform Leadership (program direction and partner selection)
• Head of Clinical Operations / VP Clinical Operations (clinical execution and vendor/partner fit)
• Drug Product Operations / Technical Operations Leadership (quality, manufacturing readiness)
• CMC Program Leadership (process development, tech transfer, scale-up planning)
• Business Development / Partnerships Directors (collaboration and BD execution)
• Chief Scientific Officer / R&D Leadership (platform decisions and innovation exchange alignment)
• Investment Directors / Managing Partners (investment evaluation and portfolio building)
• Manufacturing / CDMO Engagement Leaders (vendor selection, qualification, capacity planning)
• Data, Digital, and AI leadership (where relevant to cell/gene ops) (process digitization and operational scaling)

Industries we should map for attendee-list filtering (based on the provided Apollo-style industry list)

Using the industry categories provided, we recommend the following filters (most relevant first):

• Biotechnology (therapy developers, platform innovators)
• Pharmaceuticals (large pharma involvement, clinical commercialization planning)
• Research (academic/institute leaders when they are tied to translational programs)
• Investment Management (asset/investment decision-makers)
• Venture Capital & Private Equity (early-stage biotech investing)
• Health, Wellness & Fitness (only if the company focus is tightly linked to regenerative/therapy programs; otherwise deprioritize)
• Medical Devices (only for companies enabling therapy workflows with device/diagnostics adjacency)
• Medical Practice (only for therapy delivery centers or clinical networks, if present)
• Events Services (usually not needed for buyer selection, but can help identify sponsor/partner ecosystem vendors)

6️⃣ Estimated attendance (expected total footfall)

The official page includes 2025 event highlights with 600 attendees. Since the event is an established conference returning in 2026, we should treat ~600 attendees as the best conservative estimate for total footfall unless the 2026 brochure indicates expansion.

• Estimated total attendance (footfall): ~600 attendees
• Intimacy factor: It is intentionally “intimate,” implying fewer total attendees but typically higher concentration of senior decision-makers.
• International spread signal: 35+ countries represented (from 2025 highlights) supports cross-border buyer engagement.

7️⃣ Key focus areas & buyer engagement

Key content pillars (what buyers come to discuss)

The official event positioning states that the conference brings together advanced therapies stakeholders to discuss: innovation, investment, and bringing new treatments to market. This is reinforced by the presence of structured tracks such as Agenda sessions and curated networking experiences.

Named programming elements on the official page

• Innovation Exchange
• Investment Summit
• Women in Advanced Therapies Congress
• Experience (including networking, meetings, and meeting highlights)

How buyers are likely to engage (what actually converts)

For buyer-centric outreach and attendee-list targeting, we recommend crafting messaging around the specific conversation triggers that senior stakeholders attend for:

• Pipeline + execution readiness: “How do we accelerate translation to market while de-risking operations?”
• Manufacturing scalability: “How do we qualify and scale production capacity without compromising quality?”
• Partner selection: “Which partnerships reduce timeline risk and increase probability of success?”
• Investment diligence: “What milestones, operational readiness, and manufacturing/CMC evidence support investment decisions?”
• Platform innovation: “Where do new data/digital/process innovations create measurable acceleration?”

8️⃣ Client-product fit note (Buyer selection based on your client requirements)

We can strongly refine “Best Title to Target” and “Best buyer company list” once we know your client’s exact offering and ideal buyer persona. The official event positioning is broad, spanning therapy developers, investment, and manufacturing; therefore, the best buyer mix depends entirely on what your client sells (e.g., CDMO services, enabling technologies, recruitment solutions, analytics/data platforms, GMP consulting, clinical operations solutions, etc.).

We need from you (to finalize the best buyer segment list)

• Your client website URL (as requested)
• What the client sells in 2–3 lines (product/service + core value)
• Buyer type (is the buyer expected to be therapy developer, investor, CDMO, pharma, or provider/partner?)
• Geography preference (Europe-only vs. global accounts attending with Europe presence)

Question for you

Please share the client website we should review. After we review it, we will produce: (a) the best buyer industries from your provided industry taxonomy, (b) the highest-priority job titles, (c) a tightened buyer company shortlist aligned to your client’s ICP.

9️⃣ Final recommendation (Quality scoring + execution plan)

Overall event suitability for buyer-attendee research

Fit rating: 9/10 for advanced therapies-focused buyer intelligence because the event is intentionally curated for senior decision-makers across therapy development, investment, and manufacturing. Footfall is moderate (~600), but the decision density is typically higher than large broad conferences.

Best segments to collect (buyer persona shortlist)

• Therapeutic Developers: CEO/Co-Founder, Head of Advanced Therapies, R&D and clinical operations leadership
• Manufacturing / CMC execution stakeholders: Drug Product Operations, Technical Operations, CMC leaders, scale-up decision-makers
• Investment and partnering stakeholders: Investment Directors, Managing Partners, BD and partnerships leaders
• Innovation enablement leaders: digital/data/AI leadership where it ties to advanced therapies execution acceleration

Operational approach we recommend (so the list performs)

1. Filter by relevance to advanced therapies: cell & gene therapy, regenerative medicine, advanced manufacturing/CMC.
2. Restrict to senior decision roles: C-suite, VP/Director, Head of functions, Investment Partner roles.
3. Prioritize Europe-first accounts: align with event intent and likely meeting behavior.
4. Validate against client ICP after website review: finalize the highest conversion buyer list for your client.

Next Step: Share the client website

To complete point 8️⃣ accurately, please send your client’s website URL. We will then identify the best buyers for this specific event based on the client’s actual offerings, the most relevant job titles, and the most aligned industry filters from your provided list.